{
    "nctId": "NCT01198457",
    "briefTitle": "Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment",
    "officialTitle": "BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Prostatic Neoplasms, Multiple Myeloma, Osteolysis",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 147,
    "primaryOutcomeMeasure": "Adherence to treatment with oral clodronate (PDC, proportion of days covered).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of breast cancer, prostate cancer, multiple myeloma and other skeletal events causing tumors\n* Bone metastases\n* Therapy with clodronate (1600 mg per day, 800 mg tablets) according to SmPC (Summary of Product Characteristics) Bonefos.\n* By agreeing to usage of patients diaries and goodwill with accounting of tablets\n\nExclusion Criteria:\n\n* According to SmPC (Summary of Product Characteristics) Bonefos.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}